Benzinga · Sep 15, 2026
Needham Reiterates Buy on Alcon, Maintains $98 Price Target
Needham analyst David Saxon reiterates Alcon (NYSE:ALC) with a Buy and maintains $98 price target.
AL
NASDAQ · ALC
Alcon Inc.
Healthcare · Medical - Instruments & Supplies
$65.04
Down-$0.14 (-0.21%)
Updated Sep 20, 2026, 3:00 PM
SID Score
5.2/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 42.99B
- P/E ratio
- 43.53
- Dividend yield
- 0.51%
- 52-week range
- $61.84 – $87.64
- Volume
- 3.46M
- Avg. volume
- 1.54M
Price performance
ALC price history
1M range · 19 trading sessions · Daily adjusted prices
ALC closed at $65.04 after 19 trading sessions, down 11.75% for the selected period.
- Last close
- $65.04
- Period change
- -11.75%
- Period low
- $65.04
- Period high
- $73.70
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | $64.75 | $65.60 | $64.54 | $65.04 | 3.46M |
| Sep 17, 2026 | $66.27 | $66.275 | $64.70 | $65.18 | 2.14M |
| Sep 16, 2026 | $67.19 | $67.55 | $66.125 | $66.30 | 1.71M |
| Sep 15, 2026 | $67.06 | $67.935 | $66.95 | $67.76 | 1.51M |
| Sep 14, 2026 | $67.31 | $67.79 | $66.64 | $67.74 | 1.87M |
| Sep 11, 2026 | $67.26 | $67.415 | $65.94 | $66.03 | 1.94M |
| Sep 10, 2026 | $67.42 | $67.70 | $66.53 | $66.55 | 1.57M |
| Sep 9, 2026 | $68.90 | $69.37 | $68.255 | $68.43 | 1.96M |
| Sep 8, 2026 | $69.64 | $69.64 | $68.855 | $69.12 | 1.66M |
| Sep 4, 2026 | $70.89 | $71.14 | $70.48 | $70.50 | 1.34M |
| Sep 3, 2026 | $72.82 | $73.22 | $71.195 | $72.08 | 950.48K |
| Sep 2, 2026 | $71.72 | $73.52 | $71.72 | $72.24 | 1.33M |
| Sep 1, 2026 | $72.56 | $72.59 | $71.38 | $71.75 | 1.4M |
| Aug 31, 2026 | $71.89 | $72.45 | $71.39 | $72.06 | 1.11M |
| Aug 28, 2026 | $71.69 | $72.07 | $71.38 | $72.01 | 1.18M |
| Aug 27, 2026 | $72.46 | $72.82 | $72.16 | $72.23 | 716.52K |
| Aug 26, 2026 | $72.85 | $73.11 | $72.585 | $72.67 | 772.16K |
| Aug 25, 2026 | $73.35 | $73.4299 | $72.695 | $73.37 | 816.27K |
| Aug 24, 2026 | $73.34 | $73.91 | $73.21 | $73.70 | 1.16M |
Latest ALC news
The latest Smart Investors Daily articles mentioning ALC.
Stock researchCompany · Overview
ALC research
Overview
Company profile and research snapshot.
Company profile
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $92.35
- Implied upside
- —
- Analysts
- 5
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 13, 2026 | BERENBERG | Buy | — |
| Jul 12, 2026 | DAY BY DAY | Sell | — |
| Jul 9, 2026 | EQUITA SIM | Buy | — |
| Jun 24, 2026 | BAADER EUROPE / ALPHAVALUE | Buy | — |
| Jun 4, 2026 | NEEDHAM & COMPANY INC. | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 11, 2026
STAAR Surgical hires former CEO to lead commercial team
David Bailey has rejoined STAAR after participating in the successful campaign to block Alcon’s takeover of the company.
Yahoo · Sep 11, 2026
Bill Ackman bets AI will make this old-school business stronger
Ackman sees a hidden AI advantage in the latest addition to Pershing Square’s portfolio.
Yahoo · Sep 10, 2026
Barron’s Got Cooper Wrong but the Contact-Lens Stock Now Looks Cheap
Cooper Cos. stock has fallen about 25% since Barron’s recommended it, but a low valuation, aggressive share buybacks, and takeover potential bolster the bull case.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
